ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "COVID-19"

  • Abstract Number: 1612 • ACR Convergence 2021

    Factors Associated with COVID-19 Vaccine Hesitancy Among Individuals with Rheumatic Disease

    Kristin Wipfler1, Adam Cornish1, Alison Freifeld2, Patricia Katz3 and Kaleb Michaud2, 1FORWARD, The National Databank for Rheumatic Diseases, Omaha, NE, 2University of Nebraska Medical Center, Omaha, NE, 3University of California San Francisco, San Francisco, CA

    Background/Purpose: COVID-19 vaccination efforts are ongoing and there is a need to understand factors associated with vaccine hesitancy. Individuals with rheumatic diseases have been uniquely…
  • Abstract Number: 1928 • ACR Convergence 2021

    In Vitro and In Vivo Evidence for DOCK8 as a Risk Allele for Cytokine Storm Syndrome, Including COVID-19 and MIS-C

    Randy Cron1, Mingce Zhang1, Niansheng Chu2, Devin Absher3, John Bridges1, Amanda Schnell1, Anshul Vagrecha4, Shannon Lozinsky4, Suchitra Acharya4, Carolyn Levy4, Winn Chatham1 and Edward Behrens2, 1University of Alabama at Birmingham, Birmingham, AL, 2University of Pennsylvania, Philadelphia, PA, 3HudsonAlpha Institute for Biotechnology, Huntsville, AL, 4Hofstra/Northwell School of Medicine, Hempstead, NY

    Background/Purpose: Cytokine storm syndromes (CSS) are frequently fatal complications of a variety of oncologic, rheumatic, and infectious diseases. Many patients with CSS possess heterozygous missense…
  • Abstract Number: 0074 • ACR Convergence 2021

    Association of Anti-phospholipid Antibodies (aPL) with Poor Clinical Outcomes in Hospitalized Patients with COVID-19

    David Yaich1, Brandon Ptak1, Emma Roellke1, Erin Miller1, Juliet Kim1, Juan Gaztanaga1, Wendy Drewes1, James Ciancarelli2, Jasmin Divers1, Megan Winner1, Amy Rapkiewicz1 and Steven Carsons3, 1NYU Langone Hospital - Long Island, Mineola, NY, 2NYU Hospital Hospital- Long Island, Mineola, NY, 3NYU Long Island School of Medicine, Mineola, NY

    Background/Purpose: Critically ill patients with COVID-19 infection have a profound hypercoagulable state and can often develop thromboses in many different vascular beds. Given the presence…
  • Abstract Number: 0099 • ACR Convergence 2021

    First Results of the BELCOMID Study: BELgian Cohort Study of COVID-19 in Immune Mediated Inflammatory Diseases (IMID)

    Kurt de Vlam1, Jeroen Geldhof2, Marie Truyens3, Joao Sabino4, Marc ferrante4, Jo Lambert3, Hilde lapeere3, Tom hillary4, an Van Laethem4, Triana Lobaton3, severine vermeire4, Barbara Neerinckx1 and Patrick Verschueren5, 1University Hospitals Leuven, Leuven, Belgium, 2University Hospital Gent, Gent, Belgium, 3university hospital gent, gent, 4university hospitals leuven, leuven, 5University Hospitals Leuven - KULeuven, Leuven, Belgium

    Background/Purpose: It has been suggested that 100% of SARS-CoV2 infections leads to development of specific IgG antibodies that remain detectable for a long period of…
  • Abstract Number: 0119 • ACR Convergence 2021

    Worsened Depression but Improved Fatigue Were the Main Impacts of Severe Lockdown in Non- COVID Infected Australian Fibromyalgia Patients

    Benjamin Worcester1, Emma Guymer2 and Geoffrey Littlejohn2, 1Monash Health, Melbourne, Australia, 2Monash University, Melbourne, Australia

    Background/Purpose: To gauge the impact of severe COVID-19 related lockdown restrictions on the mental and physical wellbeing of Australian fibromyalgia patients and their recovery following…
  • Abstract Number: 0618 • ACR Convergence 2021

    Post-acute Sequelae of SARS-CoV-2 and Serological Response in a Cohort of Patients with Rheumatic Diseases

    Alice Fike1, Omer Pamuk2, Yiming Luo3, Jun Chu4, Yanira Ruiz-Perdomo3, Sarfaraz Hasni3, Pravitt Gourh3 and James Katz4, 1National Institutes of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Washington, DC, 2NIH/NIAMS, Bethesda, MD, 3National Institutes of Health, Bethesda, MD, 4National Institutes of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD

    Background/Purpose: The longitudinal experience of COVID-19 illness in patients with rheumatic diseases is emerging. Reports from the general population have described post-acute sequelae of SARS-CoV-2…
  • Abstract Number: 0961 • ACR Convergence 2021

    Proteomic Profiling of MIS-C Patients Reveals Heterogeneity Relating to Interferon Gamma Dysregulation and Vascular Endothelial Dysfunction

    Caroline Diorio1, Rawan Shraim1, Laura Vella1, Josephine Giles2, Amy Baxter2, Derek Oldridge2, Scott Canna1, Sarah Henrickson1, Kevin Mcnerney1, Frances Balamuth1, Chakkapong Burudpakdee1, Jessica Lee1, Tomas Leng1, Alvin Farrell1, Michele Lambert1, Kathleen Sullivan1, John Wherry3, David Teachey1, Hamid Bassiri1 and Edward Behrens1, 1Children's Hospital of Philadelphia, Philadelphia, PA, 2University of Pennsylvania, Philadelphia, PA, 3UPenn, Philadelphia, PA

    Background/Purpose: Multi-system Inflammatory Syndrome in Children (MIS-C) is a major complication of the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) pandemic in pediatric patients. Children…
  • Abstract Number: 1278 • ACR Convergence 2021

    Clinical Outcomes in a Cohort of Puerto Ricans with Systemic Lupus Erythematosus After SARS CoV-2 Infection

    Ariana González-Meléndez1 and Luis Vilá2, 1University of Puerto Rico Medical Sciences Campus, San Juan, PR, 2University of Puerto Rico Medical Sciences Campus, San Juan, Puerto Rico

    Background/Purpose: The coronavirus disease 2019 (COVID-19) pandemic is of particular concern for people with autoimmune rheumatic diseases and for those who are immunosuppressed given the…
  • Abstract Number: 1536 • ACR Convergence 2021

    Acceptability of Vaccines Against COVID-19 and Other Preventable Infections Among Patients with Rheumatic Disease

    Sara Tedeschi1, Jack Ellrodt1, Jacklyn Stratton1, Leah Santacroce1, Paulette Chandler1, Ellen Gravallese2 and Daniel Solomon3, 1Brigham and Women's Hospital, Boston, MA, 2Brigham and Women's Hospital, Harvard Medical School, Chestnut Hill, MA, 3Brigham and Women's Hospital, Newton, MA

    Background/Purpose: Vaccination against preventable infections is widely recommended for patients with systemic rheumatic disease. The COVID-19 pandemic has highlighted variability in attitudes toward vaccination, particularly…
  • Abstract Number: 1554 • ACR Convergence 2021

    COVID-19 Vaccine Hesitancy Among Patients with Rheumatic and Other Diseases

    Valeria Valerio1, Emmanouil Rampakakis2, Marie Hudson3, Sasha Bernatsky3, Elizabeth M. Hazel3 and Ines Colmegna4, 1Research Institute of the McGill University Health Centre, Montréal, QC, Canada, 2JSS Medical Research, Montréal, QC, Canada, 3McGill University, Montréal, QC, Canada, 4The Research Institute of the McGill University Health Centre, Montréal, QC, Canada

    Background/Purpose: Vaccination is fundamental to reduce COVID-19 risk and its complications. Vaccine hesitancy is a threat to COVID-19 vaccination uptake. We assessed the frequency of…
  • Abstract Number: 1595 • ACR Convergence 2021

    Concern About the COVID-19 Pandemic and Community Mobility Among Systemic Lupus Erythematosus Patients

    Laura Plantinga1, Courtney Hoge1, Cristina Drenkard1, Charmayne Dunlop-Thomas1, Brad Pearce1, S Sam Lim2 and C. Barrett Bowling3, 1Emory University, Atlanta, GA, 2Department of Medicine, Division of Rheumatology, Emory University School of Medicine, Atlanta, GA, 3Duke University, Durham, NC

    Background/Purpose: Opportunities for community mobility, which reflects both physical mobility and social participation, during the COVID-19 pandemic have been limited and may have been related…
  • Abstract Number: 1613 • ACR Convergence 2021

    Pandemic and Patients: Examining Health-Related Behaviors of Patients with Systemic Sclerosis During the COVID-19 Pandemic

    Nancy Dorr1, Patricia Fennell2 and Lee Shapiro3, 1The College of Saint Rose, Albany, NY, 2Albany Health Management Associates, Inc. Steffens Scleroderma Foundation, Albany, NY, 3Albany Medical College, Stillwater, NY

    Background/Purpose: Prior to COVID-19, few studies examined how patients with a chronic illness, such as systemic sclerosis (SSc), react to a pandemic. This study examined…
  • Abstract Number: 1933 • ACR Convergence 2021

    Association Between Race/Ethnicity and COVID-19 Outcomes in Systemic Lupus Erythematosus (SLE) in United States Patients: Data from the COVID-19 Global Rheumatology Alliance

    Manuel Ugarte-Gil1, Graciela Alarcn2, Andrea Seet3, Zara Izadi3, Ali Duarte-Garcia4, Emily Gilbert5, Maria Valenzuela-Almada6, Leanna Wise7, Jeffrey Sparks8, Tiffany Hsu9, Kristin D'Silva10, Naomi Patel10, Emily Sirotich11, Jean Liew12, Jonathan Hausmann13, Paul Sufka14, Rebecca Grainger15, Suleman Bhana16, Wendy Costello17, Zachary Wallace18, Lindsay Jacobsohn19, Anja Strangfeld20, Elsa Frazão Mateus21, Kimme Hyrich22, Laure Gossec23, Loreto Carmona24, Saskia Lawson-Tovey22, Lianne Kearsley-Fleet25, Martin Schaefer26, Pedro Machado27, Philip Robinson28, Milena Gianfrancesco3 and Jinoos Yazdany3, 1Hospital Guillermo Almenara Irigoyen, Essalud/Universidad Científica del Sur, Lima, Peru, 2University of Alabama at Birmingham, Birmingham, AL, 3University of California San Francisco, San Francisco, CA, 4Mayo Clinic, Rochester, MN, 5Mayo Clinic, Jacksonville, FL, 6Division of Rheumatology, Mayo Clinic, Rochester, MN, 7LAC+USC/Keck Medicine of USC, Pasadena, CA, 8Brigham and Women's Hospital, Boston, MA, 9Brigham and Women's Hospital, Jamaica Plain, MA, 10Massachusetts General Hospital, Boston, MA, 11McMaster University, Hamilton, ON, Canada, 12Boston University, Boston, MA, 13Boston Children's Hospital / Beth Israel Deaconess Medical Center, Cambridge, MA, 14HealthPartners, Eagan, MN, 15University of Otago, Wellington, New Zealand, 16Crystal Run Health, Montvale, NJ, 17Irish Children's Arthritis Network, Bansha, Ireland, 18Massachusetts General Hospital, Newton, MA, 19University of California San Francisco, Antioch, CA, 20Deutsches Rheuma-Forschungszentrum Berlin, Berlin, Germany, 21Liga Portuguesa Contra as Doenças Reumáticas (LPCDR), Lisbon, Portugal, 22University of Manchester, Manchester, United Kingdom, 23Sorbonne Université; APHP, Rheumatology Department, Pitié-Salpêtrière Hospital, Paris, France, 24Instituto de Salud Musculoesqueltica (InMusc), Madrid, Spain, 25Centre for Musculoskeletal Research, University of Manchester, Manchester, United Kingdom, 26German Rheumatism Research Center, Berlin, Germany, 27Centre for Rheumatology & Department of Neuromuscular Diseases, University College London, London, United Kingdom, 28Faculty of Medicine, The University of Queensland, Herston, Australia

    Background/Purpose: Hispanic and African American race/ethnicities have been associated with poor COVID-19 outcomes in the general population and in rheumatic disease patients within the COVID-19…
  • Abstract Number: 0075 • ACR Convergence 2021

    Endothelial Cell-activating Antibodies in COVID-19

    Hui Shi1, Yu Zuo2, Sherwin Navaz2, Alyssa Harbaugh2, Claire Hoy2, Alex Gandhi2, Gautam Sule2, Srilakshmi Yalavarthi2, Kelsey Gockman2, Jacqueline Madison2, Jintao Wang2, Melanie zuo2, Yue Shi3, Michael Maile2, Yogendra Kanthi2 and Jason Knight2, 1Division of Rheumatology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI, 2University of Michigan, Ann Arbor, MI, 3Shanghai Sports School, Shanghai, China (People's Republic)

    Background/Purpose: Patients with COVID-19 are at high risk for occlusion of vascular beds of all sizes. Considering endothelial cell activation has regularly been described as…
  • Abstract Number: 0100 • ACR Convergence 2021

    Safety of COVID-19 Vaccines After First Vaccination in Patients with Rheumatic Diseases in a Patient Reported Survey

    Rebecca Hasseli1, Bimba Franziska Hoyer2, Hanns-Martin Lorenz3, Alexander Pfeil4, Jutta Richter5, Anne Regierer6, Tim Schmeiser7, Anja Strangfeld8, Reinhard Voll9, Andreas Krause10, Hendrik Schulze-Koops11, Ulf Müller-Ladner12 and Christof Specker13, 1Justus-Liebig-University Giessen, Bad Nauheim, Germany, 2Universittsklinikum Schleswig-Holstein, Kiel, Germany, 3University Hospital Heidelberg Germany, Heidelberg, Germany, 4Friedrich Schiller University Jena, Jena, Germany, 5Rheumatology and Hiller Research Unit, Heinrich-Heine-University Duesseldorf, Medical Faculty, Duesseldorf, Germany, 6German Rheumatism Research Center, Berlin, Germany, 7Private Practice, Cologne, Germany, 8Deutsches Rheuma-Forschungszentrum Berlin, Berlin, Germany, 9Department of Rheumatology and Clinical Immunology, University Medical Center, Faculty of Medicine, Albert-Ludwigs-University of Freiburg, Freiburg, Germany, 10Immanuel Hospital, Berlin, Germany, 11Division of Rheumatology and Clinical Immunology, Department of Internal Medicine IV, University of Munich, Munich, Germany, 12JLU Giessen, Campus Kerckhoff, Dept. Rheum & Clin Immunol, Bad Nauheim, Germany, 13Evangelisches Krankenhaus, Kliniken Essen-Mitte, Essen, Germany

    Background/Purpose: Among patients with rheumatic and musculoskeletal diseases (RMDs) and their treating physicians, concerns prevail about the effectiveness and safety of vaccination against COVID-19, especially…
  • « Previous Page
  • 1
  • …
  • 22
  • 23
  • 24
  • 25
  • 26
  • …
  • 38
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology